Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsWPS Health Insurance Prior Auth Policy Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentWPS Health InsurancePolicy N/A

    Prior Authorization Requirements for Pharmacy and Medical Benefit Drugs

    Customize your policy alerts

    Sign up for all WPS Health Insurance policy alerts

    Know when WPS Health Insurance releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines why and how prior authorization (PA) is used for drugs covered under WPS Health Insurance, who performs reviews, and how to obtain PA criteria or assistance. Affects providers, pharmacies, and members whose prescriptions may require PA.

    Policy Summary
    PayerWPS Health Insurance
    PolicyPrior Authorization Requirements for Pharmacy and Medical Benefit Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to the reviewer indicated for each drug (Express Scripts, CCUM, eviCore) or direct to WPS if the PBM/vendor cannot complete the review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All drugs on the listRequire prior authorization
    1-800-475-1954Primary reviewer contact number
    10/1/2025Effective date shown
    ESI / eviCore / CCUMExample reviewers
    J-codes
    HCPCS codes present

    Coverage Criteria

    General PA coverage criteria

    Covered when PA requirements met and medical necessity established

    PA and medical necessity: Prior authorization must be obtained and documentation must support medical necessity; experimental, investigational, or unproven services are excluded.

    All drugs on the listed require PA and are reviewed by designated reviewers (ESI, CCUM, eviCore, or WPS) depending on benefit/vendor.

    General PA and reviewer routing

    Coverage and authorization requirements summarized for listed drugs

    PA requirement and reviewer routing: All drugs listed require prior authorization and have an assigned reviewer vendor (ESI, CCUM, eviCore) or should be directed to WPS if the reviewer cannot complete the review.

    Reviewer option (ESI option 1, CCUM option 2, eviCore option 3) varies by drug as noted in the listing

    Administrative PA and reviewer routing

    Covered when prior authorization is obtained and routed to the designated reviewer

    PA routing and review: Request must include PA and be submitted to the reviewer specified for the drug (ESI, CCUM, or eviCore). If the reviewer cannot complete the review, route to WPS for evaluation.

    No clinical criteria in these chunks; this is routing/administrative guidance.

    Prior Authorization and Reviewer Routing

    Coverage of drugs listed is managed via prior authorization and routed to specified reviewers

    PA routing requirements: All listed drugs require prior authorization and must be submitted to the reviewer listed (ESI, CCUM, or eviCore). If the reviewer cannot complete the review, the request should be directed to WPS for evaluation.

    Applies to entries in this excerpt

    General PA requirement (excerpt)

    Covered when prior authorization is obtained from the designated reviewer for each drug.

    PA required: All drugs listed require prior authorization and reviewer assignment is specified per drug (ESI, CCUM, eviCore, or WPS).

    Refer to vendor-specific reviewer options; if vendor cannot complete review, escalate to WPS.

    General PA requirement

    Covered when PA is obtained and routed to the designated reviewer

    PA routing and requirement: Prior authorization required for all listed drugs and must be submitted to the PBM reviewer indicated for each drug (ESI, CCUM, eviCore) or to WPS when PBM review is unavailable.

    No clinical indication-specific criteria in this excerpt.

    Prior Authorization — Listed Drugs

    Drugs listed in this document segment are subject to prior authorization and routed to the reviewer/PBM specified for each drug.

    PA requirement for listed drugs: All drugs in this list require prior authorization; submit to the reviewer indicated (ESI, CCUM, or eviCore) or to WPS if the PBM cannot complete the review.

    Reviewer contact number 1-800-475-1954 appears for PBM reviewer options.

    Prior Authorization Routing Requirement

    Covered when prior authorization is obtained and routed to the listed reviewer

    PA routing: All drugs shown require prior authorization and must be submitted to the reviewer specified (ESI, CCUM, eviCore, or WPS).

    If the listed reviewer cannot complete review it should be referred to WPS.

    Prior Authorization and Reviewer Assignment

    Covered when prior authorization is obtained and routed to the designated reviewer/vendor per the list

    PA routing: All listed drugs require prior authorization and must be routed to the reviewer/vendor indicated (ESI, eviCore, CCUM, or WPS) depending on the drug.

    Routing determines which vendor completes the PA review; oncology drugs frequently route to eviCore.

    Prior authorization is used to confirm that a requested drug meets the payer's medical necessity requirements. Services and treatments deemed experimental, investigational, or unproven under applicable clinical guidelines do not meet medical necessity and will not be covered.

    When a group uses a PBM other than Express Scripts (ESI) through WPS, providers must follow that PBM's own prior authorization processes and submission requirements. The document repeatedly instructs: If using a PBM other than Express Scripts (ESI) through WPS, refer to the other PBM for PA handling and routing.

    For entries routed to vendors other than ESI (for example CCUM or eviCore) the instruction is the same: follow the other PBM/vendor's processes. Where a different PBM is responsible, PA submission, clinical documentation requirements, and reviewer contact should follow that PBM's procedures rather than Express Scripts.

    All drugs listed in the excerpt require prior authorization before coverage will be considered. There are no additional clinical coverage criteria included in these specific excerpts; the primary requirement across entries is that a PA be submitted to the designated reviewer for the drug.

    Certain agents are routed to specialized management programs. Oncology and gene‑therapy products are frequently routed to eviCore (oncology vendors) or CCUM as indicated in the listing; providers must submit PA requests to the reviewer noted for those programs and follow any eviCore/CCUM routing instructions shown.

    If a delegated reviewer (ESI, CCUM, or eviCore) cannot complete the prior‑authorization review, the request should be escalated to WPS for evaluation. The listings repeatedly instruct providers to route requests to WPS when the delegated PBM/vendor is unable to complete the review.

    The document states consistently that prior authorization is required for all drugs listed; each PA must be submitted to the reviewer specified for that drug (Express Scripts, CCUM, eviCore) or to WPS if the PBM cannot complete the review. Include required identifiers (e.g., HCPCS/J‑code and drug name) and clinical documentation with the PA submission as directed.

    Treatments considered experimental, investigational, or unproven do not meet medical necessity and are therefore not covered. Prior authorization determinations rely on clinical documentation, FDA labeling, and published literature or evidence‑based guidelines to establish whether a requested service meets medical necessity.

    Coding (HCPCS / J-codes)

    Sample HCPCS codes from drug listHCPCS
    J3490HCPCS Code for 5-fluorouracil topical (as listed)
    Additional HCPCS codesHCPCS
    J8499HCPCS Code listed for abacavir/dolutegravir/lamivudi
    Adalimumab HCPCS codesHCPCS
    J0135HCPCS Code for adalimumab
    J0139HCPCS Code for adalimumab
    ADAMTS13 recombinant codesHCPCS
    J7171HCPCS Code for ADAMTS13 recombinant-krhn
    C9167HCPCS Code for ADAMTS13 recombinant-krhn
    Covered HCPCS codes (selected from excerpt)HCPCS
    J7171ADAMTS13 recombinant-krhn
    C9167ADAMTS13 recombinant-krhn
    J3490adapalene (listed under misc HCPCS J3490)
    Covered HCPCS codes (continued)HCPCS
    J9354ado-trastuzumab emtansine (KADCYLA)
    J0172aducanumab-avwa (ADUHELM)
    J7352afamelanotide acetate (SCENESSE)
    Covered HCPCS/Q-codes and J-codesHCPCS
    Q2057afamitresgene autoleucel (TECELRA)
    j8999afatinib oral (coded as miscellaneous J-code j8999)
    Q5147aflibercept-ayyh (PAVBLU) biosimilar
    Q5155aflibercept-jbvf (AVTOZMA) biosimilar
    Q5150aflibercept-mrbb (AHZANTIVE) biosimilar
    Q5153aflibercept-vszy (OPUVIZ) biosimilar
    J0180agalsidase beta (FABRAZYME)
    Additional HCPCS / J-codesHCPCS
    J0220alglucosidase alfa (MYOZYME)
    J0221alglucosidase alfa (LUMIZYME)
    J8499multiple oral/injectable medications listed under general J8499 or misc
    J3590anakinra (KINERET) listed under J3590
    Hemophilia, biologics, and oncology J-codesHCPCS
    J7207antihemo fviii, full length peg
    J7185antihemophil/factor VIII related codes
    J7192antihemophil/factor VIII related codes
    J7209antihemoph:fviii, hek b-delete (NUWIQ)
    J7210antihem.fviii, sin-chn, b-dm tru (AFSTYLA)
    J9061amivantamab-vmjw (RYBREVANT)
    J0491anifrolumab-fnia (SAPHNELO)
    J0207amifostine (ETHYOL)
    J0257alphal-proteinase inhibitor (GLASSIA)
    HCPCS / J-codes referenced in excerptHCPCS
    J7185HCPCS code listed for certain antihemophilic factor products
    J7192HCPCS code listed for certain antihemophilic factor products
    J7209HCPCS code listed (NUWIQ)
    J7190HCPCS code for antihemophilic factor (human) / KOATE family
    J7182HCPCS code for recombinant antihemophilic factor
    J7211HCPCS code listed for recombinant antihemophilic factor
    J7191HCPCS code for some antihemophilic factor/ahf entries
    J7183HCPCS for antihemophilic factor/vwf
    J7186HCPCS for antihemophilic factor/vwf
    J7187HCPCS for antihemophilic factor/vwf
    1–10 of 29
    1/3
    HCPCS/Codes (excerpt)HCPCS
    J8499HCPCS code listed for multiple agents (placeholder non-specific drug code) as shown in document
    J2782HCPCS code for avacincaptad pegol
    C9162Listed alongside J2782 for avacincaptad pegol
    J0219HCPCS code for avalglucosidase alfa-ngpt
    j8999HCPCS miscellaneous code listed for avapritinib oral and other oral oncology agents
    Additional HCPCS/Codes (excerpt)HCPCS
    J3490HCPCS unspecified drug code used for multiple topical/injectable agents
    J9037HCPCS code for belantamab mafodotin-blmf
    J0485HCPCS code for belatacept
    J0490HCPCS code for belimumab
    J9032HCPCS code for belinostat
    J9056HCPCS code for bendamustine hcl
    J9058HCPCS code for bendamustine hcl (Apotex)
    J9059HCPCS code for bendamustine hcl (Baxter)
    J3393HCPCS code for betibeglogene autotemcel
    Q2041Code for axicabtagene ciloleucel (CAR-T)
    1–10 of 18
    1/2
    Examples from B entries (bevacizumab-tnjn)HCPCS
    J3590HCPCS code listed for bevacizumab-tnjn
    J9999Alternate HCPCS code listed for bevacizumab-tnjn
    Bexarotene and other B entriesHCPCS
    J3490HCPCS code listed for bexarotene topical and multiple other entries
    j8999HCPCS code used for pharmacy-to-medical crosswalk for several oral agents
    HCPCS codes for listed oncology and specialty drugsHCPCS
    J9040bleomycin
    J9041bortezomib (Velcade)
    J9044bortezomib alternate
    J9042brentuximab vedotin
    J1632brexanolone
    C9073brexucabtagene autoleucel
    J8499bosentan and many small-molecule entries
    J9043cabazitaxel
    J0584burosumab-twza (CrysVita)
    J8520capecitabine
    1–10 of 17
    1/2
    Listed HCPCS/CPT/Q codesHCPCS
    J9047carfilzomib
    Listed HCPCS/CPT/Q codesHCPCS
    J9050carmustine
    J9052carmustine
    C9399carmustine in polifeprosan 20 (GLIADEL)
    Listed HCPCS/Q codesHCPCS
    J1426casimersen
    C9075casimersen
    Q0240casirivimab/imdevimab
    Q0243casirivimab/imdevimab
    Q0244casirivimab/imdevimab
    Misc HCPCS codes used as catch-allHCPCS
    J8499celecoxib / cenobamate / chenodiol (as listed)
    J9119cemiplimab-rwlc
    J3490cenegermin-bkbj / ciclesonide inhalation / ciclesonide nasal / other miscellaneous
    CAR-T and oncology HCPCS codesHCPCS
    C9098ciltacabtagene autoleucel
    Q2056ciltacabtagene autoleucel
    J1203cipaglucosidase alfa-atga
    J9060cisplatin
    Coagulation factor HCPCS codesHCPCS
    J9027clofarabine
    J7195coagulation factor ix (recombinant)
    J7213coagulation factor ix (recombinant)
    J7189coagulation factor recomb viia / coagulation factor viia, recombinant
    Additional HCPCS codesHCPCS
    J7175coagulation factor X
    J7212coagulation viia, recomb-jncw
    J9057copanlisib
    J0775collagenase clostridium histolyticum
    Final codes in excerptHCPCS
    J1307crovalimab-akkz
    j8999ceritinib oral / crizotinib oral (placeholder miscellaneous code)
    J0791crizanlizumab-tmca
    Listed HCPCS codesHCPCS
    J0791crizanlizumab-tmca HCPCS code
    Listed HCPCS codesHCPCS
    j8999crizotinib oral HCPCS code
    Cyclophosphamide HCPCS codesHCPCS
    J9070cyclophosphamide inj HCPCS code
    J9075cyclophosphamide inj HCPCS code
    J9071cyclophosphamide inj (auromedic) HCPCS code
    J9076cyclophosphamide inj (baxter) HCPCS code
    Miscellaneous HCPCS codesHCPCS
    J8499multiple non-specific oral/OTC HCPCS mapping used in list
    J9100cytarabine HCPCS code
    j9098cytarabine-liposome HCPCS code
    J0850cytomegalovirus immune globulin HCPCS code
    J0889daprodustat HCPCS code
    Oncology and specialty HCPCS codesHCPCS
    J9145daratumumab HCPCS code
    J9144daratumumab and hyaluronidase-fihj HCPCS code
    J0881darbepoetin alfa HCPCS code
    J0882darbepoetin alfa HCPCS code
    J9011datopotamab deruxtecan-dlnk HCPCS code
    C9174datopotamab deruxtecan-dlnk alternate HCPCS/HCPCS-like code
    J9150daunorubicin HCPCS code
    J9153daunorubicin/cytarabine lipos HCPCS code
    j0589daxibotulinumtoxinA-lanm HCPCS code
    C9160daxibotulinumtoxinA-lanm alternate code
    1–10 of 12
    1/2
    Oral oncology HCPCS codesHCPCS
    j8999decitabine and cedazuridine oral HCPCS code
    Common HCPCS (J8499) entriesHCPCS
    J8499HCPCS code listed for multiple drugs (general drug code placeholder) as provided in document
    Specified HCPCS codesHCPCS
    J1413delandistrogene moxeparvovec-rokl
    Denosumab HCPCSHCPCS
    J0897denosumab
    Denosumab-bbdz multiple HCPCS/CPT-like codesHCPCS
    C9399denosumab-bbdz listed
    J3490denosumab-bbdz listed
    J3590denosumab-bbdz listed
    J9999denosumab-bbdz listed
    Denosumab-bmwo HCPCSHCPCS
    Q5157denosumab-bmwo
    Denosumab-bnht HCPCSHCPCS
    Q5158denosumab-bnht
    Denosumab-dssb and desmopressin codesHCPCS
    Q5159denosumab-dssb
    J8499desmopressin acetate (listed)
    Misc HCPCSHCPCS
    L8605dextranomer/hyaluronate/nacl (DEFLUX SOLESTA)
    Doxorubicin HCPCSHCPCS
    J9000doxorubicin hcl
    Q2050doxorubicin hcl (liposomal)
    Dornase alfa HCPCSHCPCS
    J7639dornase alfa
    Eculizumab and biosimilars HCPCSHCPCS
    J1299eculizumab (SOLIRIS)
    J1300eculizumab (SOLIRIS)
    Q5151eculizumab-abzv (biosimilar)
    Q5139eculizumab-aeeb (biosimilar)
    Q5152eculizumab-aeeb (biosimilar)
    Edaravone and related codesHCPCS
    J1301edaravone
    C9493edaravone (alternate code)
    J9361efbemalenograstim alfa-vuxw (RYZNEUTA)

    Provider Actions & Submission Instructions

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required — All drugs on this list require prior authorization (PA). Failure to obtain PA may result in denial of coverage. Providers must include the drug name and applicable HCPCS/NDC codes on the PA request.

    • All drugs listed require prior authorization (PA).
    • Include HCPCS (or NDC where applicable) and the drug name on the PA submission.
    Documentation Required

    Routing and Documentation / Submission Routing and Documentation

    Reviewer Routing & Submission Instructions — Submit PA requests to the reviewer indicated for the specific drug (Express Scripts / ESI, CCUM, or eviCore). If the delegated PBM/vendor (ESI, CCUM, or eviCore) cannot complete the review, route the request to WPS for evaluation. For PA or step therapy criteria for drugs reviewed by ESI or CCUM, call 1-800-475-1954. For eviCore clinical guidelines visit https://www.evicore.com/provider/clinical-guidelines and search WPS Health Insurance.

    Initial Therapy Criteria

    Initial authorization (administrative)

    Administrative: PA required prior to initiation

    PA requirement: Prior authorization must be obtained before dispensing/administration and routed to the specified reviewer (ESI, CCUM, or eviCore).

    No clinical initiation criteria provided in these chunks.

    lenacapavir initiation requirement

    Operational note for lenacapavir initiation

    lenacapavir initiation: Initiation dosing requires combination with injectable dose or combined with oral dose for initiation as noted; PA/review should account for combined initiation regimen.

    Step Therapy & Prior Authorization Process

    InstructionContact / Action
    For drugs reviewed by Express Scripts or Care Continuum
    Call 1-800-475-1954 to speak with a prior authorization specialist to obtain prior authorization and step therapy criteria details.
    ScenarioRequired Provider Action
    When the member's plan uses a PBM other than Express Scripts (ESI) through WPS
    Refer the request to that PBM and follow that PBM's prior authorization processes; if the delegated PBM cannot complete the review route to WPS for evaluation.
    ObservationNotes from source
    Some oral oncology and supportive-care agents list different reviewer paths for oncology vs non-oncology
    Entries indicate oncology routing to eviCore and non-oncology routing to ESI/CCUM, but no explicit step therapy rules are provided in the excerpt.
    Coverage requirementSubmission routing
    Prior authorization required before coverage
    Submit prior authorization to the reviewer specified for each drug (ESI, CCUM, or eviCore) as listed in the document.
    RequirementProvider action
    PA required prior to dispensing or administration
    Follow the specific reviewer routing shown for each drug entry (ESI, CCUM, or eviCore); include HCPCS/CPT/Q-code and drug name on the PA request.
    StatementImplication
    Step therapy regimens are not listed in this excerpt
    No step therapy steps are provided for the drugs shown; contact the reviewer (see routing) for any step therapy details.
    General ruleRouting / Escalation
    All listed drugs require prior authorization
    Route PA requests to the reviewer assigned per drug (ESI, CCUM, eviCore, or WPS); if the PBM/vendor cannot complete review, direct the request to WPS for evaluation.
    Routing noteReviewer assignment
    Oncology and complex specialty drug requests
    Routed to eviCore (option 3) or CCUM (option 2) depending on the drug; if the delegated vendor cannot complete review, escalate to WPS.
    SummaryProvider responsibility
    Reviewer assignment varies by drug; prior authorization is required
    Submit PA to the assigned reviewer/vendor prior to benefit payment; follow the routing and include required documentation and billing code information.

    Site-of-Care & Benefit Type Notes

    Note
    Note
    Note
    Note
    Note

    Biosimilar Entries & Notes

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background

    Prior authorization is used to ensure appropriate use of certain drugs and to determine whether a requested drug meets the payer's medical necessity requirements. The PA review considers medical records, prior treatments, FDA labeling, and peer‑reviewed literature; failure to obtain required PA for any drug on this list may result in denial of coverage.

    Definitions & Abbreviations

    Prior authorization
    DefinitionA review process to determine if a drug meets medical necessity requirements before coverage is approved.
    When usedPrior authorization must be obtained before dispensing/administration for drugs on the PA list.
    Decision inputsMedical records, FDA labeling, peer-reviewed literature, and evidence-based guidelines are considered during review.
    Benefit Type
    DefinitionIndicates whether the product is covered under the Pharmacy (P) benefit, Medical (M) benefit, or both as shown in the entries.
    UsageBenefit type is listed on each drug line to determine billing and reviewer routing (P = Pharmacy, M = Medical).

    Revision History

    2025-10-01effective_dateLatest

    Policy effective date updated to 10/1/2025 as shown in multiple document segments.

    2025-10-01content_update

    Drug listing segments updated to note prior authorization requirement and reviewer routing (ESI, CCUM, eviCore) with the effective date 10/1/2025.

    2025-10-01content_update
    Policy Summary
    PayerWPS Health Insurance
    PolicyPrior Authorization Requirements for Pharmacy and Medical Benefit Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to the reviewer indicated for each drug (Express Scripts, CCUM, eviCore) or direct to WPS if the PBM/vendor cannot complete the review.
    SourceLink
    On This Page
    Coverage CriteriaCoding (HCPCS / J-codes)Provider Actions & Submission InstructionsInitial Therapy CriteriaStep Therapy & Prior Authorization ProcessSite-of-Care & Benefit Type NotesBiosimilar Entries & NotesBackgroundDefinitions & AbbreviationsRevision History
    Sample HCPCS/Codes from segmentHCPCS
    Q5151eculizumab-abzv (biosimilar) HCPCS Code
    Q5139eculizumab-aeeb (biosimilar) HCPCS Code
    Q5152eculizumab-aeeb (biosimilar) HCPCS Code
    J1301edaravone HCPCS Code
    Additional HCPCS/CodesHCPCS
    J9361efbemalenograstim alfa-vuxw (biosimilar) HCPCS Code
    J1449eflapegrastim-xnst HCPCS Code
    J3490eladocagene exuparvovec-tneq / elivaldogene autotemcel / eplontersen miscellaneous HCPCS
    J3590eladocagene exuparvovec-tneq / elivaldogene autotemcel / eplontersen miscellaneous HCPCS
    C9399elapegademase-Ivlr / elivaldogene autotemcel / eplontersen unclassified HCPCS
    Oncology HCPCS CodesHCPCS
    J1323elranatamab-bcmm HCPCS Code
    C9165elranatamab-bcmm HCPCS Code
    J9176elotuzumab HCPCS Code
    J9177enfortumab vedotin-ejfv HCPCS Code
    J9321epcoritamab-bysp HCPCS Code
    C9155epcoritamab-bysp HCPCS Code
    Additional HCPCS CodesHCPCS
    J9178epirubicin HCPCS Code
    J3490epoprostenol sodium / other miscellaneous HCPCS
    J1325epoprostenol sodium HCPCS Code
    J0885epoetin alfa HCPCS Code
    Q5105epoetin alfa-epbx HCPCS Code
    Misc HCPCS CodesHCPCS
    J9179eribulin mesylate HCPCS Code
    J1325epoprostenol sodium (glycine) HCPCS Code
    S0013esketamine HCPCS Code
    J3032eptinezumab-jjmr HCPCS Code
    Sample HCPCS codes in excerptHCPCS
    J8499HCPCS code referenced for multiple oral/other drugs (placeholder unknown specific billing)
    S0013HCPCS code for esketamine (SPRAVATO)
    J3490HCPCS code referenced for estradiol gel and others
    Additional HCPCS codesHCPCS
    J1438HCPCS code for etanercept (ENBREL)
    J0606HCPCS code for etelcalcetide hydrochloride (PARSABIV)
    J1428HCPCS code for eteplirsen (EXONDYS 51)
    Hemostasis product HCPCS codesHCPCS
    J7194HCPCS for factor IX complex (PROFILNINE)
    J7203HCPCS for factor IX human pegylated (REBINYN)
    J7178HCPCS for fibrinogen concentrate (RIASTAP)
    Additional HCPCS codesHCPCS
    J7177HCPCS for fibrinogen (FIBRYGA)
    J1414HCPCS for fidanacogene elaparvovec (BEQVEZ)
    J1442HCPCS for filgrastim (NEUPOGEN)
    HCPCS codes listedHCPCS
    C9173filgrastim-txid HCPCS (listed)
    Q5148filgrastim-txid HCPCS (listed)
    J8499multiple drugs listed with J8499 as HCPCS
    J7174fitusiran HCPCS
    J9200floxuridine HCPCS
    J9185fludarabine phosphate HCPCS
    J7311fluocinolone acetonide HCPCS
    S0128follistim HCPCS
    S0126follitropin alfa HCPCS
    J1434fosaprepitant HCPCS
    1–10 of 32
    1/4
    Covered HCPCS Codes (examples in this section)HCPCSCovered
    J8499glecaprevir/pibrentasvir, miscellaneous HCPCS noted
    J9286glofitamab-gxbm
    J1610glucagon (GVOKE)
    Additional HCPCS CodesHCPCSCovered
    C9293glucarpidase
    J8499glutamine, glycerol phenylbutyrate, grass pollen, others mapped to J8499
    J3590golimumab
    J1602golimumab (SIMPTONI ARIA)
    J1429golodirsen (VYONDYS 53)
    Immune globulins and other HCPCS CodesHCPCSCovered
    J1627granisetron subcutaneous (SUSTOL)
    J3490granisetron transdermal (SANCUSO), imiquimod
    J1628guselkumab (TREMFYA)
    J1640hemin (PANHEMATIN)
    J9226histrelin acetate
    J9225histrelin implant
    J1746ibalizumab-uiy (TROGARZO)
    J1744icatibant acetate (FIRAZYR / SAJAZIR)
    J9208ifosfamide
    J1575igg/hyaluronidase recombinant (HYQVIA)
    1–10 of 26
    1/3
    Immune globulins (examples)HCPCS
    J1559HCPCS Code listed for an immune globulin product (CUTAQUIG alt descriptions present in chunk)
    J1551HCPCS Code listed for an immune globulin product (CUTAQUIG reference)
    Immune globulins and related HCPCSHCPCS
    J1576HCPCS Code for an immune globulin product (PANZYGA reference)
    J1599HCPCS Code for an immune globulin product (PANZYGA reference)
    J1566HCPCS Code for GAMMAGARD S-D
    Additional immune globulin HCPCS codesHCPCS
    J1460GAMASTAN / GAMASTAN S-D HCPCS codes listed
    J1560GAMASTAN HCPCS code listed
    J1561GAMUNEX-C / GAMMAKED HCPCS code listed
    J1558XEMBIFY HCPCS code listed
    Mixed HCPCS codes and j8999 placeholdersHCPCS
    j8999Miscellaneous HCPCS J-code placeholder used for some oral oncology agents (e.g., inavolisib, infigratinib)
    J1306HCPCS code listed for inclisiran (LEQVIO)
    J0588HCPCS for incobotulinumtoxin A (XEOMIN)
    J1823HCPCS for inebilizumab-cdon (UPLIZNA)
    Oncology and biologic HCPCS codesHCPCS
    J1745Infliximab HCPCS code (REMICADE)
    Q5104Infliximab-abda HCPCS code (RENFLEXIS)
    J1748Infliximab-dyyb HCPCS code
    Q5103Alternate HCPCS for infliximab-dyyb
    C9399Inotersen sodium HCPCS code listed
    J9229Inotuzumab ozogamicin HCPCS code
    Insulins and interferons HCPCSHCPCS
    J3490Insulin and insulin analog HCPCS placeholder
    J9214Interferon alfa-2b HCPCS code
    J1826Interferon beta-1a HCPCS code
    J1830Interferon beta-1b HCPCS code
    J9216Interferon gamma HCPCS code
    Mixed oncology and other agent HCPCS codesHCPCS
    J8499HCPCS placeholder used for several oral or miscellaneous agents (e.g., iptacopan, istradefylline)
    J9206Irinotecan HCPCS code
    J9205Irinotecan liposome HCPCS code
    J9227Isatuximab HCPCS code
    J8499Also used for istradefylline example
    Miscellaneous biologics and radiopharmaceutical kit codesHCPCS
    J3590Ixekizumab HCPCS code
    A9596Kit prep of Ga-68/gozetotide HCPCS code (ILLUCCIX)
    J0593Lanadelumab HCPCS code (TAKHZYRO)
    J1930Lanreotide HCPCS code (SOMATULINE DEPOT)
    J1932Lanreotide (CIPLA) HCPCS code
    J1931Ilaronidase HCPCS code (ALDURAZYME)
    Sample HCPCS codes in listHCPCS
    J0593lanadelumab-flyo
    J1930lanreotide
    J1932lanreotide (cipla)
    Additional HCPCS/J-codesHCPCS
    j8999lapatinib oral (coded generically)
    J1931Ilaronidase
    Lenacapavir and othersHCPCS
    J0738lenacapavir (listed with J0752 in other lines)
    J0752lenacapavir
    J9153liposome-encapsulated daunorubicin and cytarabine (VYXEOS)
    J3490multiple entries use this generic code (e.g., liraglutide, lifitegrast)
    Radiation/theranostic HCPCS codesHCPCS
    C9031lutetium lu 177 dotatate (LUTATHERA)
    A9513lutetium lu 177 dotatate
    A9607lutetium lu 177 vipivotide tetraxetan
    A9699lutetium lu 177 vipivotide tetraxetan (other)
    HCPCS / J-codes present in excerptHCPCS
    J8499HCPCS code listed for multiple drugs (placeholder for unclassified biologics/other)
    J9223lurbinectedin
    C9031lutetium lu 177 dotatate
    A9513lutetium lu 177 dotatate
    A9607lutetium lu 177 vipivotide tetraxetan
    A9699lutetium lu 177 vipivotide tetraxetan
    J2182mepolizumab
    J2170mecasermin
    J9250methotrexate sodium
    J9260methotrexate sodium
    1–10 of 25
    1/3
    Effective Date — 10/1/2025
    Effective date10/1/2025
    Applies toCoding and listed drug entries in document segments referencing this effective date
    Source noteShown on document segment: 'Effective Date: 10/1/2025'
    Effective Date — 10/1/2025
    Effective date10/1/2025
    Applies toGene therapy and related entries in the referenced segment
    Source noteEffective date appears in the segment containing delandistrogene moxeparvovec-rokl and related entries
    Effective Date — 10/1/2025
    Effective date10/1/2025
    Applies toEntries in the segment listing hemin, histrelin, imatinib mesylate and related drugs
    Source noteSegment includes the line: 'Effective Date: 10/1/2025'
    Effective Date — (placeholder)
    Effective date(no effective date found in cited chunks)
    Applies toPlaceholder entry — source chunk indices not specified
    Source noteNo supporting chunk index available in brief for this placeholder key/value
    • Submit PA to the reviewer shown for each drug (ESI, CCUM, or eviCore).
    • If the PBM/vendor cannot complete the review, direct the request to WPS for evaluation.
    • For PA/step therapy details for ESI/CCUM-reviewed drugs call 1-800-475-1954.
    • For eviCore clinical criteria: https://www.evicore.com/provider/clinical-guidelines (search WPS Health Insurance)
    Documentation Required

    Medical Necessity and Experimental/Investigational Exclusions

    Documentation Considered in PA Review — Medical records documenting the patient’s condition and prior treatments, FDA labeling, published peer-reviewed literature, and evidence-based guidelines will be used in the PA medical necessity determination. Services deemed experimental, investigational, and/or unproven are not covered.

    • Medical records describing diagnosis and prior therapies are required.
    • FDA-approved labeling, peer-reviewed literature, and evidence-based guidelines will be reviewed.
    • Services considered experimental, investigational, or unproven under clinical guidelines are not covered.
    Billing Rule

    Reviewer Routing and HCPCS Codes (examples)

    Drug-specific Routing Notes — Certain drugs have specified reviewers and HCPCS codes. Providers must follow the reviewer routing shown for each drug when submitting PA requests.

    • Example entries from the drug list: lanadelumab-flyo (HCPCS J0593) — Reviewer: ESI (option 1).
    • lanreotide (HCPCS J1930) and lanreotide (cipla) (HCPCS J1932) — Reviewer: CCUM (Non-Oncology, option 2) or eviCore (Oncology, option 3) per comments.
    • lapatinib (oral, HCPCS J8999) — Reviewer: eviCore (option 3).
    • glofitamab-gxbm (HCPCS J9286) — Reviewer: eviCore (option 3).
    Note

    Routing Noted; Step Therapy Rules

    Routing noted; no step therapy rules in excerpt — Some oncology oral agents and other drugs are routed to eviCore (oncology) versus ESI/CCUM (non-oncology). The excerpt does not contain explicit step therapy rules; contact the reviewer (or 1-800-475-1954 for ESI/CCUM) for step therapy criteria.

    • Oncology vs non-oncology routing may determine reviewer (eviCore for oncology).
    • No step therapy rules are present in this excerpt — obtain criteria from the designated reviewer.
    Prior Authorization

    Escalation when PBM/Vendor Cannot Complete Review

    Escalation Path — If the delegated PBM/vendor (ESI, CCUM, or eviCore) cannot complete the prior authorization review, providers must direct the request to WPS for evaluation using the contact information provided on the member’s ID card or 1-800-475-1954 as appropriate.

    • When ESI, CCUM, or eviCore cannot complete review, route to WPS for evaluation.
    • Use the contact on the member’s insurance card or the general PA line where indicated.
    Note

    How to Obtain Step Therapy and PA Criteria

    How to obtain PA/Step Therapy Criteria — For drugs reviewed by Express Scripts or Care Continuum (CCUM), call 1-800-475-1954 to speak with a prior authorization specialist for detailed PA and step therapy criteria. For eviCore-reviewed drugs, use eviCore’s provider site as noted above. Confirm gene therapy coverage with WPS Customer Service.

    • ESI/CCUM PA and step therapy details: 1-800-475-1954.
    • eviCore clinical guidelines: https://www.evicore.com/provider/clinical-guidelines.
    • Confirm gene therapy coverage with WPS Customer Service via the number on the member’s card.
    ExampleEntries show 'Benefit Type P = Pharmacy' and medical benefit HCPCS codes when applicable.
    Benefit Type — Code key
    DefinitionBenefit Type P = Pharmacy; M = Medical
    PurposeClarifies which payer benefit (pharmacy or medical) applies to the listed product
    ApplicationUsed to determine whether PA is routed through PBM or medical reviewer and billing method
    HCPCS / J-code
    DefinitionHCPCS/J-codes listed are the billing codes associated with the medical benefit for the specified product.
    UsageInclude the HCPCS/J-code on the PA request when submitting for medical benefit drugs.
    ExampleSegment shows 'HCPCS Code = J1413' for delandistrogene moxeparvovec-rokl.
    Abbreviations used in routing
    AbbreviationsPA = prior authorization; PBM = pharmacy benefit manager; ESI = Express Scripts; CCUM = CareCentrix utilization management; eviCore = specialty/utilization management vendor.
    Routing impactThese abbreviations identify the reviewer/vendor to which PA requests should be submitted per drug entry.
    EscalationIf ESI, CCUM, or eviCore cannot complete the review, requests should be directed to WPS for evaluation.

    Entries for specific products (e.g., delandistrogene moxeparvovec-rokl, imatinib mesylate, chenodiol, hemin) include reviewer assignments and the instruction to direct reviews to WPS if delegated PBMs cannot complete them, effective 10/1/2025.